Tropanserin

Tropanserin (INN; MDL-72,422) is a drug which acts as a potent and selective 5-HT3 receptor antagonist.[1] It was investigated in clinical trials for the treatment of migraine in the 1980s but was never marketed.[2]

Not to be confused with Tropisetron.
Tropanserin
Clinical data
ATC code
  • None
Identifiers
IUPAC name
  • [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 3,5-dimethylbenzoate
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC17H23NO2
Molar mass273.376 g·mol−1
3D model (JSmol)
SMILES
  • CN3[C@H]1CC[C@@H]3C[C@@H](C1)OC(=O)c2cc(C)cc(C)c2
InChI
  • InChI=1S/C17H23NO2/c1-11-6-12(2)8-13(7-11)17(19)20-16-9-14-4-5-15(10-16)18(14)3/h6-8,14-16H,4-5,9-10H2,1-3H3/t14-,15+,16+
  • Key:HDDNYFLPWFSBLN-ZSHCYNCHSA-N

Synthesis

Tropanserin can be prepared by the reaction of tropine with 3,5-dimethylbenzoyl chloride.

Tropanserin synthesis[3]

See also

References
  1. King FD, Jones BJ, Sanger GJ (22 October 1993). 5-Hydroxytryptamine-3 Receptor Antagonists. CRC Press. p. 244. ISBN 978-0-8493-5463-2. Retrieved 6 May 2012.
  2. Johnson G (1 August 1987). "Recent Advances in Migraine Research". In Bailey DM (ed.). Annual Reports in Medicinal Chemistry. Vol. 22. Academic Press. p. 44. doi:10.1016/S0065-7743(08)61153-7. ISBN 978-0-08-058366-2.
  3. US 4563465, Fozard JR, Gittos MW, "Treatment of migraine with substituted tropyl benzoate derivatives", issued 7 January 1986, assigned to Merrell Dow Pharma



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.